SAN DIEGO, July 08, 2025--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, ...
Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation ...
SAN DIEGO, February 05, 2026--(BUSINESS WIRE)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat ® KMT2A + MRD ...
Cancer diagnostic company Invivoscribe is partnering with Japanese technology company Hitachi High-Tech. Invivoscribe said May 9 that the deal is aimed at accelerating the molecular diagnostics and ...
Invivoscribe Appoints Loui Madakamutil to Lead Its Therapeutics Division as Chief Scientific Officer
Invivoscribe, Inc., an industry pioneer in developing and commercializing diagnostic products and reagents for hematological malignancies, announced today key members of the leadership team hired to ...
Invivoscribe's companion diagnostic is an in vitro PCR test which detects both ITD mutations and TKD mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained ...
SAN DIEGO, July 21, 2023 /PRNewswire/ -- Invivoscribe is excited to announce that the LeukoStrat ® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in ...
SAN DIEGO, May 19, 2020 /PRNewswire/ -- Invivoscribe to offer the LeukoStrat ® CDx FLT3 Mutation Assay as an FDA approved kit with analysis software. In 2017, Invivoscribe's LeukoStrat ® CDx FLT3 ...
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results